Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma

Table 4 Univariate and multivariate Cox regression analysis of clinical characteristics with progression-free survival as the dependent variable

Independent variables	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Group (LeSiIT/BeSiIT)	0.876 (0.460-1.670)	0.688
Tumor size (> 10/≤ 10 cm)	1.143 (0.597-2.187)	0.687
Tumor number (> 3/≤ 3)	0.759 (0.369-1.561)	0.453
Gender (male/female)	0.969 (0.404-2.321)	0.943
Age (years)	0.989 (0.961-1.017)	0.432
Age (≥ 65/< 65 years)	0.878 (0.425-1.813)	0.725
Etiology (yes/no)	0.559 (0.196-1.598)	0.278
Liver cirrhosis (yes/no)	0.735 (0.375-1.440)	0.369
Metastasis (yes/no)	0.767 (0.391-1.504)	0.440
Vascular invasion (yes/no)	1.041 (0.554-1.957)	0.900
Child-Pugh (B/A)	1.390 (0.655-2.951)	0.391
BCLC stage (C/B)	0.869 (0.432-1.750)	0.694
ECOG PS
0	Reference	-
1	1.562 (0.772-3.163)	0.215
2	NA	0.972
ALBI grade
1	Reference	-
2	0.668 (0.343-1.301)	0.235
3	1.643 (0.382-7.069)	0.505
AFP concentration (ng/mL)	1.000 (1.000-1.000)	0.042a	1.000 (1.000-1.000)	0.191
AFP (> 28.0/≤ 28.0 ng/mL)	1.754 (0.830-3.708)	0.141
CEA (> 3.6/≤ 3.6 ng/mL)	1.645 (0.811-3.338)	0.168
AFCE
0	Reference	-	Reference	-
1	3.255 (1.244-8.516)	0.016a	2.973 (1.120-7.888)	0.029a
2	6.153 (2.011-18.821)	0.001a	5.746 (1.865-17.708)	0.002a

^aP value less than < 0.05, and it is statistically significant.

PFS: Progression-free survival; HR: Hazard ratios; BeSiIT: Bevacizumab plus sintilimab plus interventional treatment; LeSiIT: Lenvatinib plus sintilimab plus interventional treatment; BCLC: The Barcelona Clinic Liver Cancer; ECOG PS: Eastern Cooperative Oncology Group Performance Status; NA: Not available; ALBI: Albumin-bilirubin; AFP: Α-fetoprotein; CEA: Carcinoembryonic antigen; AFCE: Α-fetoprotein and carcinoembryonic antigen score.